- Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
-
Cho YK
- KMID: 2428757
- Clin Mol Hepatol.
- 2018 Sep;24(3):299-301.
- doi: 10.3350/cmh.2018.1006
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
-
Sayari S, Neishaboori H, Jameshorani M
- KMID: 2428761
- Clin Mol Hepatol.
- 2018 Sep;24(3):331-338.
- doi: 10.3350/cmh.2018.0006
BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin... -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
-
Oh JY
- KMID: 2175442
- Diabetes Metab J.
- 2011 Jun;35(3):298-299.
- doi: 10.4093/dmj.2011.35.3.298
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
-
Kim JH
- KMID: 2174025
- Diabetes Metab J.
- 2015 Aug;39(4):304-306.
- doi: 10.4093/dmj.2015.39.4.304
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
-
Chung HS, Lee MK
- KMID: 2281649
- Diabetes Metab J.
- 2011 Aug;35(4):411-417.
- doi: 10.4093/dmj.2011.35.4.411
BACKGROUND: To evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period. METHODS: Our study design involved... -
- CITED
-
- Close
- SHARE
-
- Close
- Metformin induced acute pancreatitis and lactic acidosis in a patient on hemodialysis
-
Lee YK, Lim K, Hwang SH, Ahn YH, Shin GT, Kim H, Park IW
- KMID: 2328110
- Yeungnam Univ J Med.
- 2016 Jun;33(1):33-36.
- doi: 10.12701/yujm.2016.33.1.33
Metformin, commonly prescribed for type 2 diabetes, is considered safe with minimal side-effect. Acute pancreatitis is rare but potentially fatal adverse side-effect of metformin. We report a patient on hemodialysis... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparisons of Efficacy between Dapagliflozin and Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus Patients
-
Kang BK, An SH, Kim JY, Gwak HS
- KMID: 2387590
- Korean J Clin Pharm.
- 2017 Jun;27(2):99-104.
- doi: 10.24304/kjcp.2017.27.2.99
OBJECTIVE: This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozin combination and the metformin/sitagliptin combination in type 2 diabetic patients. METHODS: This study retrospectively reviewed... -
- CITED
-
- Close
- SHARE
-
- Close
- Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
-
Yang HK, Lee SH, Shin J, Choi YH, Ahn YB, Lee BW, Rhee EJ, Min KW, Yoon KH
- KMID: 2454058
- Diabetes Metab J.
- 2019 Jun;43(3):287-301.
- doi: 10.4093/dmj.2018.0054
BACKGROUND: We evaluated the efficacy and safety of acarbose add-on therapy in Korean patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with metformin and sitagliptin. METHODS: A total... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
-
Kim HM, Lim JS, Lee BW, Kang ES, Lee HC, Cha BS
- KMID: 2407109
- Endocrinol Metab.
- 2015 Mar;30(1):84-91.
- doi: 10.3803/EnM.2015.30.1.84
BACKGROUND: Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
-
Yang HK, Kang B, Lee SH, Kim HS, Yoon KH, Cha BY, Cho JH
- KMID: 2174030
- Diabetes Metab J.
- 2015 Aug;39(4):335-341.
- doi: 10.4093/dmj.2015.39.4.335
BACKGROUND: This study aimed to evaluate the effect of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, on insulin secretion and glucagon suppression in Korean subjects with type 2 diabetes mellitus. METHODS: Twenty-four... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Influencing Glycemic Control Response of Sitagliptin
-
Kim GW, Kim JH, Lee MY, Shin JY, Shin YG, Ha EH, Chung CH
- KMID: 2173938
- J Korean Diabetes.
- 2013 Dec;14(4):206-211.
- doi: 10.4093/jkd.2013.14.4.206
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
-
Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR
- KMID: 2281714
- Diabetes Metab J.
- 2011 Apr;35(2):159-165.
- doi: 10.4093/dmj.2011.35.2.159
BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. While... -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
-
Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, Yoo JS, Nam JS, Cho MH, Park JS, Ahn CW, Kim KR
- KMID: 2175444
- Diabetes Metab J.
- 2011 Jun;35(3):300-301.
- doi: 10.4093/dmj.2011.35.3.300
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
-
Choe EY, Cho Y, Choi Y, Yun Y, Wang HJ, Kwon O, Lee BW, Ahn CW, Cha BS, Lee HC, Kang ES
- KMID: 2280692
- Diabetes Metab J.
- 2014 Jun;38(3):211-219.
- doi: 10.4093/dmj.2014.38.3.211
BACKGROUND: We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus. METHODS: A total of 170 type 2... -
- CITED
-
- Close
- SHARE
-
- Close
- Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008–2016
-
Yi H, Lee JH, Shin JY
- KMID: 2431637
- Yonsei Med J.
- 2019 Feb;60(2):200-207.
- doi: 10.3349/ymj.2019.60.2.200
PURPOSE: Cardiovascular adverse events (AEs) after use of dipeptidyl peptidase-4 (DPP4) inhibitors have been reported and suspected since the launch of DPP-4 inhibitors in 2006. However, few studies have investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of DPP-4 Inhibitors
-
Kim NH, Kim SG
- KMID: 2173918
- J Korean Diabetes.
- 2013 Sep;14(3):111-119.
- doi: 10.4093/jkd.2013.14.3.111
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These... -
- CITED
-
- Close
- SHARE
-
- Close
- Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug
-
Kim HJ, Baek EB, Kim SJ
- KMID: 2430094
- Korean J Physiol Pharmacol.
- 2018 Nov;22(6):713-719.
- doi: 10.4196/kjpp.2018.22.6.713
Dipeptidyl peptidase4 (DPP4) inhibitors such as gemigliptin are anti-diabetic drugs elevating plasma concentration of incretins such as GLP-1. In addition to the DPP4 inhibition, gemigliptin might directly improve the functions... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
-
Ha KH, Kim B, Shin HS, Lee J, Choi H, Kim HC, Kim DJ
- KMID: 2414908
- Korean Circ J.
- 2018 May;48(5):395-405.
- doi: 10.4070/kcj.2017.0324
BACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly... -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutics for Diabetes Using Incretin Hormone
-
Oh S
- KMID: 2259281
- Korean J Med.
- 2011 Jun;80(6):625-634.
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types: GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Effect of Single-dose Sitagliptin Administration on Gastric Emptying: Crossover Study Using the 13C Breath Test
-
Nonaka T, Sekino Y, Iida H, Yamada E, Ohkubo H, Sakai E, Higurashi , Hosono K, Endo H, Koide T, Takahashi , Fujita K, Yoneda M, Goto A, Kusakabe A, Kobayashi , Gotoh E, Maeda S, Nakajima A, Nosaka C, Inamori M
- KMID: 2325795
- J Neurogastroenterol Motil.
- 2013 Apr;19(2):227-232.
BACKGROUND/AIMS: The gastrointestinal motility effects of endogenous incretin hormones enhanced by dipeptidyl peptidase-IV (DPP-IV) inhibitors have not yet been sufficiently investigated. The aim of this study was to determine whether... -
- CITED
-
- Close
- SHARE
-
- Close
